Why the study?
Does the level of Cisd2 expression affect cardiac aging and electromechanical functioning in mice?
Does the level of Cisd2 expression affect cardiac aging and electromechanical functioning in mice?
Cisd2 is essential for maintaining cardiac electromechanical function and delaying cardiac aging, identifying it as a potential novel drug target for age-related cardiac dysfunction.
Cisd2 loss impairs cardiac electromechanical function in mice; leaves open its relevance as a therapeutic target in human cardiomyopathy.
CDGSH iron-sulfur domain-containing protein 2 (Cisd2) is pivotal to mitochondrial integrity and intracellular Ca2+ homeostasis. In the heart of Cisd2 knockout mice, Cisd2 deficiency causes intercalated disc defects and leads to degeneration of the mitochondria and sarcomeres, thereby impairing its electromechanical functioning. Furthermore, Cisd2 deficiency disrupts Ca2+ homeostasis via dysregulation of sarco/endoplasmic reticulum Ca2+-ATPase (Serca2a) activity, resulting in an increased level of basal cytosolic Ca2+ and mitochondrial Ca2+ overload in cardiomyocytes. Most strikingly, in Cisd2 transgenic mice, a persistently high level of Cisd2 is sufficient to delay cardiac aging and attenuate age-related structural defects and functional decline. In addition, it results in a younger cardiac transcriptome pattern during old age. Our findings indicate that Cisd2 plays an essential role in cardiac aging and in the heart's electromechanical functioning. They highlight Cisd2 as a novel drug target when developing therapies to delay cardiac aging and ameliorate age-related cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: